title: Vaginal Health During Breast Cancer Treatment.
abstract: There are increasing numbers of breast cancer survivors. Chemotherapy or endocrine therapy result in effects on vaginal health that may affect quality of life. These effects may impact sexual function, daily comfort, or the ability to perform a pelvic examination. Vulvovaginal atrophy, or genitourinary syndrome of menopause, may be treated with nonhormonal or hormonal measures. Breast cancer survivors who are menopausal and/or on endocrine therapy should be screened for issues with vaginal health and counseled about treatment options.
authors.affiliation: Adult Survivorship Program, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02115, USA. sfalk@partners.org.
authors.forename: Sandy J
authors.initials: SJ
authors.lastname: Falk
authors.affiliation: Adult Survivorship Program, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02115, USA.
authors.forename: Sharon
authors.initials: S
authors.lastname: Bober
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008593:Menopause; D011788:Quality of Life; D017741:Survivors; D014621:Vagina / Q000187:drug effects* / Q000503:physiopathology; D014623:Vaginal Diseases / Q000175:diagnosis / Q000503:physiopathology; D014845:Vulvar Diseases / Q000175:diagnosis / Q000503:physiopathology
chemical_list: D018931:Antineoplastic Agents, Hormonal
keywords: Breast cancer; Conjugated equine estrogens; Dyspareunia; Genitourinary syndrome of menopause; Menopause; Premature ovarian failure; Vaginal dryness; Vaginal estrogen therapy; Vaginal lubricants; Vulvovaginal atrophy